<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593619</url>
  </required_header>
  <id_info>
    <org_study_id>HSREB13767</org_study_id>
    <nct_id>NCT00593619</nct_id>
  </id_info>
  <brief_title>Trial Comparing the Safety of Two Different Intravenous Iron Formulations</brief_title>
  <official_title>A Randomized Double-Blind Safety Comparison of Intravenous Iron Dextran Versus Iron Sucrose in an Adult Non-Hemodialysis Outpatient Population: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>London Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the safety profile using equal doses of intravenous
      iron dextran versus iron sucrose. The researchers hypothesize that significantly more
      patients receiving intravenous iron dextran (using the current intermediate molecular weight
      product) will have severe adverse outcomes than patients receiving iron sucrose in the adult
      non-hemodialysis outpatient population. Secondly, since these severe reactions may require
      additional nursing time and physician interventions that may negate any cost advantage of
      iron dextran, the researchers hypothesize that iron sucrose will be more cost-effective than
      iron dextran.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Interim Analysis and review by Data Safety Monitoring Board
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of severe adverse drug reactions (ADRs)</measure>
    <time_frame>Immediate - during infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse drug reactions (ADRs)</measure>
    <time_frame>Immediate and delayed - within 24hrs post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anaphylactic/anaphylactoid ADRs</measure>
    <time_frame>Immediate - during infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of combined mild and moderate ADRs</measure>
    <time_frame>Immediate - during infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delayed ADRs</measure>
    <time_frame>delayed - within 24hrs post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause mortality</measure>
    <time_frame>Immediate and delayed - within 24hrs post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician and nursing time required to manage ADRs</measure>
    <time_frame>Immediate and delayed - within 24hrs post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response in laboratory parameters</measure>
    <time_frame>Within 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>Completion of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <condition>Perioperative Blood Conservation</condition>
  <arm_group>
    <arm_group_label>Iron Dextran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron Sucrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron dextran</intervention_name>
    <description>300mg in 250cc normal saline given over 2 hours</description>
    <arm_group_label>Iron Dextran</arm_group_label>
    <other_name>Infufer, Sandoz Canada Incorporated, DIN 02221780</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose</intervention_name>
    <description>300mg in 250cc normal saline given over 2 hours</description>
    <arm_group_label>Iron Sucrose</arm_group_label>
    <other_name>Venofer, Luitpold Pharmaceuticals Inc., DIN 02243716</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 100

          -  To be receiving intravenous iron

        Exclusion Criteria:

          -  Age &lt; 18

          -  Hemodialysis

          -  Previous exposure to intravenous iron

          -  Unable to provide written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian H Chin-Yee, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fiona E Ralley, MB ChB, FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cyrus C Hsia, MD,FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>March 2, 2009</last_update_submitted>
  <last_update_submitted_qc>March 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ian H. Chin-Yee, Chair/Chief of Hematology</name_title>
    <organization>London Health Sciences Centre</organization>
  </responsible_party>
  <keyword>Intravenous Iron</keyword>
  <keyword>Safety</keyword>
  <keyword>Perioperative</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>Non hemodialysis population</keyword>
  <keyword>Perioperative blood conservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
    <mesh_term>Iron-Dextran Complex</mesh_term>
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

